Peroxisome proliferator-activated receptor ligands in atherosclerosis.
In this review, the effect of peroxisome proliferator-activated receptor (PPAR) ligands on atherosclerosis is examined. The PPAR-gamma agonist thiazolidinediones are currently indicated for the management of Type 2 diabetes mellitus, and the PPAR-alpha agonist fibrates are used in dyslipidaemia. Here their mechanism of action and the pre-clinical and clinical evidence for the use of these medications for the prevention and treatment of atherosclerotic disease is explored. In addition, the role of PPAR-delta and the possibilities for the role of dual-binding agonists are examined.
Viles-Gonzalez
Juan F
JF
Cardiovascular Biology Research Laboratory, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Choi
Brian G
BG
Fuster
Valentin
V
Badimon
Juan J
JJ
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D004727:Endothelium / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008024:Ligands; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists / Q000378:metabolism*
D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors